FY2025 EPS Estimates for BioLineRx Lifted by HC Wainwright

BioLineRx Ltd. (NASDAQ:BLRX) – Equities researchers at HC Wainwright raised their FY2025 earnings estimates for shares of BioLineRx in a report issued on Monday, March 31st. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of ($3.52) for the year, up from their previous forecast of ($5.20). HC Wainwright has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for BioLineRx’s current full-year earnings is ($5.80) per share.

Other analysts have also recently issued reports about the company. Jones Trading restated a “hold” rating on shares of BioLineRx in a research report on Wednesday. StockNews.com lowered BioLineRx from a “hold” rating to a “sell” rating in a report on Tuesday, March 18th.

BioLineRx Price Performance

Shares of NASDAQ:BLRX opened at $2.65 on Thursday. The firm’s 50 day moving average is $3.40 and its two-hundred day moving average is $10.36. The firm has a market capitalization of $8.82 million, a P/E ratio of -0.30 and a beta of 1.39. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. BioLineRx has a 52 week low of $2.58 and a 52 week high of $35.60.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BioLineRx stock. Highbridge Capital Management LLC bought a new position in BioLineRx Ltd. (NASDAQ:BLRX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned 50.50% of BioLineRx at the end of the most recent reporting period. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.